OBI Pharma, Inc.

Taipei Exchange 4174.TWO

OBI Pharma, Inc. Net Income for the year ending December 31, 2023: USD -34.09 M

OBI Pharma, Inc. Net Income is USD -34.09 M for the year ending December 31, 2023, a 44.98% change year over year. Net income is the total profit earned by a company after deducting all expenses, including taxes and non-controlling interest.

OBI Pharma, Inc. Net Income for the year ending December 31, 2022 was USD -61.96 M, a 0.02% change year over year.
OBI Pharma, Inc. Net Income for the year ending December 31, 2021 was USD -61.97 M, a -17.00% change year over year.
OBI Pharma, Inc. Net Income for the year ending December 31, 2020 was USD -52.97 M, a -10.06% change year over year.
OBI Pharma, Inc. Net Income for the year ending December 31, 2019 was USD -48.13 M, a -20.41% change year over year.

Key data

Date	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)	Net Income Margin

Taipei Exchange: 4174.TWO

OBI Pharma, Inc.

CEO	Dr. Heidi Wang Ph.D.
IPO Date	Dec. 12, 2012
Location	Taiwan
Headquarters	No. 3, Park Street
Employees	260
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

OBI Pharma, Inc., a biopharma company, develops and licenses novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally. It offers Adagloxad Simolenin (OBI-822), a breast cancer active immunity anti-cancer drug for generating antibody against tumor carbohydrate antigen Globo H; OBI-833, an immunity anti-cancer drug for the treatment of lung cancer; OBI-866 SSEA-4, an active immune-oncology drug; OBI-888, a passive immunotherapy monoclonal antibody designed for targeting Globo H; OBI-999, an antibody drug conjugate; OBI-3424, a micromolecule chemotherapy prodrug; and OBI-858, a botulinum toxin, as well as OBI-898 and OBI-998 drugs. The company was founded in 2002 and is headquartered in Taipei, Taiwan.

Key trends

Past 5 years